Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07283497
PHASE4

Itraconazole Therapy In Bronchiectasis With Airway Mold

Sponsor: Mayo Clinic

View on ClinicalTrials.gov

Summary

The primary objective of this study is to evaluate the feasibility of itraconazole therapy in patients with bronchiectasis and airway mold. Feasibility will be assessed through recruitment success, treatment adherence, tolerability, and participant retention. The study will also explore the impact on respiratory symptoms and airway microbiome diversity.

Official title: Itraconazole Therapy In Bronchiectasis With Airway Mold: A Single-Arm Pilot Trial Of Feasibility, Safety, And Impact On Respiratory Symptoms And Airway Microbiome Diversity

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-03-15

Completion Date

2030-12-31

Last Updated

2026-02-10

Healthy Volunteers

No

Interventions

DRUG

Itraconazole 200 mg

Subjects will receive oral itraconazole, 200 mg twice daily, for six weeks, based on prior dosing regimens for airway fungal disease.

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States